Want to know more about a novel innate checkpoint #IGSF8, our clinical-stage program and the story of how we utilize #AI in this drug discovery journey? Talk to our CEO Dr. Xiaole Shirley Liu.
At #AACR24, we will deliver an oral presentation on our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting IGSF8. AACR continues to be one of the most prestigious cancer meetings, and we are thrilled to showcase our program and this exciting target. See you in San Diego! More details here: https://lnkd.in/gXAx-dBF #AACR24 #oncology American Association for Cancer Research
